What is HHC-O: properties, action and what science knows about it

What is HHC-O: properties, action and what science knows about it

The cannabinoid market is developing extremely rapidly. Along with the well-known CBD, CBG and THC, new compounds are emerging, the properties of which are only just beginning to be studied in detail. One of them is HHC-O (HHCO) - hexahydrocannabinol acetate, which has become prominent among semi-synthetic cannabinoids in recent years.

There are many conflicting claims surrounding HHC-O. It is credited with relaxing, pain-relieving, and other effects, and is sometimes even called a non-psychoactive alternative to THC. The problem is that there is very little clinical data on HHC-O. Therefore, it is important to separate the results of scientific studies from marketing claims and subjective user experiences.

What is HHC-O?

HHC-O, HHC-O-acetate or HHCO is the acetate derivative of HHC (hexahydrocannabinol). HHC, in turn, is a hydrogenated analogue of THC. In natural raw materials, HHC can only be found in trace amounts, while commercial HHC and HHC-O are usually associated with the chemical transformation of other cannabinoids.

Therefore, HHC-O is more correctly classified as a semi-synthetic cannabinoid. European drug monitoring authorities also consider it to be in this group of new psychoactive substances.

How is HHC-O different from HHC?

The main difference lies in the chemical structure. HHC-O is the acetate ester of HHC. That is, the HHC molecule is additionally modified with an acetyl group.

Metabolism studies show an interesting feature: HHC-O can be rapidly converted to HHC. Because of this, researchers suggest that HHC-O may behave as a kind of prodrug, and some of its effects after entering the body may be related to the already formed HHC.

This is one of the reasons why evaluating the properties of HHC-O based solely on its activity in laboratory tests is not enough.

How is HHC-O obtained?

HHC-O should not be described as a regular hemp extract like traditional CBD extracts. It involves the chemical modification of cannabinoids.

The preparation of HHC-O by acylation of HHC has been described in the scientific literature, and historically HHC acetates have also been prepared by catalytic hydrogenation of THC acetates. The specific composition of the commercial product may depend on the raw materials used, the production technology, and subsequent purification.

This is why laboratory control and identification of impurities are especially important for semi-synthetic cannabinoids. An insufficiently purified product could theoretically contain residual reagents or by-products of chemical reactions.

Does HHC-O have a psychoactive effect?

The claim that HHC-O has no psychoactive effects at all cannot be considered substantiated today.

In a study of the activity of semisynthetic cannabinoids at human CB1 receptors, individual HHC-O epimers showed little or no direct activity. However, the authors raised another possibility: HHC acetate may act as a prodrug and, after metabolic conversion, form HHC.

And HHC is already characterized by cannabimimetic activity associated with CB1 receptors. Therefore, the lack of strong direct activity of HHC-O in a laboratory model does not mean the absence of a psychoactive effect after its entry into the body.

HHC-O and CBD - what's the difference?

Therefore, it is wrong to equate CBD and HHC-O. These are compounds that differ in chemical properties, pharmacology, and level of research.

What effects are attributed to HHC-O?

HHC-O is often described online as a substance that can induce relaxation, mood changes, drowsiness, or other effects similar to those of THC and HHC. There are also claims that it can affect physical discomfort, sleep, stress, and appetite.

However, most of these claims cannot be equated with proven therapeutic efficacy. There are not enough high-quality human clinical trials of HHC-O to recommend it for the treatment of pain, insomnia, anxiety, or other conditions.

What is known about the interaction of HHC-O with CB1 receptors?

CB1 is one of the key receptors in the endocannabinoid system. Its activation is largely responsible for the psychoactive effects of THC.

In a laboratory study of HHC, HHC-P, and HHC-O, it was found that the different spatial forms of these molecules behaved differently. For HHC-O, direct activation of CB1 was small or non-existent depending on the epimer.

However, metabolic studies have shown rapid conversion of HHC-O to HHC, supporting the hypothesis that acetate may act as a precursor to a more active compound.

How well researched is HHC-O?

Compared to CBD or THC, there is very little. Even for HHC, there is significantly less information on pharmacology and toxicology than for classical cannabinoids, and for its acetate derivatives, the gaps are even greater.

Scientists still need to establish the pharmacokinetics of HHC-O in humans, the actual psychoactive effect profile, short- and long-term risks, potential drug interactions, and the effects of different routes of use.

What risks may be associated with HHC-O?

One of the main problems is not only the substance itself, but also the composition of the products it is contained in. Semi-synthetic cannabinoids are obtained through chemical transformations, so the quality of purification and laboratory control are critical.

Acetate cannabinoids in vaping products require special attention. Scientific reviews point to potential risks associated with thermal decomposition of acetate esters. However, specific studies on the pulmonary toxicity of HHC-O are still lacking.

Due to the lack of toxicological data, it is not possible to establish a universal “safe dose” of HHC-O or to guarantee the absence of adverse reactions.

Is HHC-O legal?

The legal status of HHC-O is complex and rapidly changing. It is not possible to simply assume that the substance is derived from hemp cannabinoids or that a particular product contains little delta-9-THC.

HHC and related semi-synthetic cannabinoids are regulated differently in different countries. Some European countries have already introduced controls on HHC, and regulators continue to monitor the emergence of HHC-O, HHC-P and other new derivatives.

Therefore, before purchasing or using such products, it is necessary to check the current legislation of a specific country.

HHC-O, HHC and THC: can they be compared?

Structural similarity does not mean identical effects. Delta-9-THC remains the much better studied cannabinoid. Much less is known about HHC, and information about HHC-O is even more limited.

It is also incorrect to claim that HHC-O is guaranteed to be “stronger” or “weaker” than THC. The final effect can be influenced by the composition of the product, the ratio of epimers, metabolism, the amount of substance, and the individual characteristics of the organism.

Frequently Asked Questions about HHC-O

What does HHC-O mean?

HHC-O is the short name for hexahydrocannabinol acetate. It is a chemically modified derivative of HHC.

Is HHC-O a natural cannabinoid?

Commercial HHC-O is more correctly characterized as a semi-synthetic cannabinoid. Its production involves chemical modification of the original cannabinoid compound.

Are HHC-O and HHC the same thing?

No. HHC-O is an acetate derivative of HHC. However, metabolic studies show that HHC-O can be rapidly converted to HHC in the body.

Is HHC-O psychoactive?

It should not be considered guaranteed non-psychoactive. Although the direct activity of HHC-O on CB1 in laboratory studies was small, the substance can be metabolized to HHC, which has cannabimimetic activity.

Can HHC-O be used to treat pain or insomnia?

There is currently insufficient clinical evidence to recommend HHC-O as a treatment for pain, insomnia, anxiety disorders, or other conditions.

Is HHC-O safe?

There is insufficient data to draw such a conclusion. The long-term safety, toxicology, and possible interactions of HHC-O with other substances require further research.

HHC-O is an interesting but still understudied member of a new generation of semi-synthetic cannabinoids. Scientific data is helping to better understand its chemical structure and metabolism, but information about its effects on humans is still lacking.

It is especially important not to directly transfer the properties of CBD, HHC, or THC to HHC-O. This is a separate compound for which the pharmacological profile, toxicological risks, and long-term safety have yet to be determined.

Therefore, loud claims about the medicinal properties, guaranteed safety, or lack of psychoactive effects of HHC-O today are ahead of scientific evidence. At the Effectplants blog, we recommend evaluating new cannabinoids primarily based on research results, not marketing promises.